11th Nov 2013 11:38
LONDON (Alliance News) - GW Pharmaceuticals PLC said Monday that it had commenced a Phase 1b/2a clinical trial for the treatment of recurrent glioblastoma multiforme, meaning tumours that arise from the abnormal growth of the glial tissue of the brain.
The company said that recurrent glioblastoma multiforme accounts for around 50% of new cases of brain cancer in the US each year.
"We are very excited about moving this compound into further human study and the prospects of cannabinoids as a potential treatment to inhibit tumour growth," said Director of Research and Development Stephen Wright in a statement.
Shares in GW Pharmaceuticals were trading up 0.75 pence at 146.75 pence Monday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright © 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
GWP.L